Abstract
Chronic HCV infection affects 130-170 million individuals worldwide and there are currently 34 million people living with HIV/AIDS. The aim of treatment of HCV is the elimination of the virus (sustained virological response). With development of drugs that specifically target HCV replication, direct-acting agents, sustained virological response rates have dramatically changed for genotype 1 infections. Challenges in the use of direct-acting agents in patients with HIV/HCV co-infection include the potential for drug-drug interactions between HIV and HCV drugs, additional drug toxicities and the need for therapy with IFN-α. Faldaprevir (FDV), previously known as BI 201335, is a second-wave HCV NS3/4A protease inhibitor with highly potent in vitro activity against HCV GT-1a/1b and improved pharmacokinetics suitable for once-daily dosing. FDV is currently in Phase III development. This article will review the pharmacology and pharmacodynamics of FDV, the efficacy and safety of the drug and explore possible future developments in the management of chronic hepatitis C infection, focusing on HIV/HCV co-infected patients.
References
Sep 25, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y BenhamouT Poynard
Feb 15, 2003·Journal of Hepatology·Thierry PoynardUNKNOWN PANFIBROSIS Group
Oct 28, 2003·Nature·Daniel LamarreMontse Llinàs-Brunet
Sep 29, 2005·The Journal of Biological Chemistry·George KukoljPierre L Beaulieu
Dec 15, 2005·Journal of Hepatology·Miriam J Alter
Sep 5, 2008·The Journal of Infectious Diseases·Vincent SorianoUNKNOWN EuroSIDA Study Group
Feb 12, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Daniel Lavanchy
Nov 6, 2009·Antiviral Research·Vincent SorianoPablo Barreiro
Apr 13, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·UNKNOWN Antiretroviral Therapy Cohort Collaboration
Aug 19, 2010·Journal of Medicinal Chemistry·Montse Llinàs-BrunetPeter W White
Sep 9, 2010·Antimicrobial Agents and Chemotherapy·Peter W WhiteGeorge Kukolj
Dec 15, 2010·Journal of Hepatology·Michael P MannsWulf O Boecher
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Apr 20, 2011·Journal of Medical Virology·F BolcicJ Quarleri
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Oct 13, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jianmin DuanMichael G Cordingley
Jan 1, 2013·Antiviral Research·Milan J SonneveldHarry L A Janssen
Jan 30, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mark S SulkowskiWulf O Böcher
Feb 15, 2013·The Journal of Infectious Diseases·Mark S Sulkowski
Mar 19, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mark S SulkowskiWulf O Böcher
Aug 16, 2013·The New England Journal of Medicine·Stefan ZeuzemFederico J Mensa